Multidisciplinary personalized approach in the management of vulvar cancer – the Vul.Can Team experience
- 30 May 2020
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 30 (7), 932-938
- https://doi.org/10.1136/ijgc-2020-001465
Abstract
Introduction Multidisciplinary treatment strategy involving adjuvant radiotherapy for advanced vulvar cancer could be useful in offering the best personalized clinical approach. In 2013, the VULvar CANcer Multi-Disciplinary Team (Vul.Can MDT) was set up in our institution, in order to share knowledge and expertise, high-quality diagnosis, and evidence-based decision making in the context of personalized medicine. The aim of this observational study was to report on our series of vulvar cancer patients managed postoperatively with radiotherapy within the framework of a formal multidisciplinary tumor board. Methods Coupling surgical and oncological international guidelines with “case-by-case” discussions, a multi-specialist consensus was progressively reached and internal recommendations were developed and introduced in the daily routine. Data from vulvar cancer patients who underwent primary surgery and adjuvant radiotherapy throughout a 5-year period were retrospectively collected. Actuarial local control was the primary endpoint, while secondary end-points were acute and late toxicities, disease-free survival, and overall survival. Toxicity was evaluated according to the Common Toxicity Criteria Adverse Event v 4.0 scale. Results The analysis included 35 patients with squamous vulvar cancer treated with adjuvant radiotherapy±chemotherapy, from April 2013 to September 2017. Median age was 70 years (range 18–87), all patients underwent surgery followed by concomitant chemoradiation (45.7%) or radiotherapy alone (54.3%). The median prophylactic dose on lymphatic drainage was 45 Gy, while positive nodes and perineal area received 51.2 Gy and 52.6 Gy, respectively. Chemotherapy involved the cisplatin-based regimen (45.7%)±5-fluorouracil (37.1%). Median follow-up was 32 months (range 6–72): the 24-months local control, disease-free survival, and actuarial overall survival rates were 88.6%, 82.0%, and 91.0%, respectively. Low rates of severe acute (12%) and late (3%) toxicities occurred. Discussion The outcomes of this series support the benefit of a multidisciplinary personalized approach in the management of vulvar cancer.Keywords
This publication has 27 references indexed in Scilit:
- Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysisGynecologic Oncology, 2015
- Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 StudyJNCI Journal of the National Cancer Institute, 2015
- MITHRA – multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility studyJournal of Contemporary Brachytherapy, 2015
- An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: Is tumor size significance being underrated?Gynecologic Oncology, 2014
- An Algorithmic Approach to Perineal Reconstruction After Cancer Resection—Experience From Two International CentersAnnals of Plastic Surgery, 2013
- Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: Impact on outcome and treatment-related complicationsEuropean Journal of Surgical Oncology, 2012
- Radiation Therapy Compared With Pelvic Node Resection for Node-Positive Vulvar CancerObstetrics & Gynecology, 2009
- The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinomaGynecologic Oncology, 2006
- Radical vulvectomy with postoperative irradiation for vulvar cancer: Therapeutic implications of a central blockInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulvaGynecologic Oncology, 1990